Latest Advances on Anticancer Drugs in Clinical Development

Marbella, Spain, November 3rd- 4th, 2016

www.esocmarbella.com

• CHAIRMEN

Dr. Hernán Cortés Funes, Hospital Universitario 12 de Octubre, Madrid, Spain
Dr. Luis Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, Spain
Dr. José Antonio López-Martín, Hospital Universitario 12 de Octubre, Madrid, Spain

Organized by:

GrupOncoSur
Hospital Universitario 12 de Octubre
i+12
Instituto de Investigación Hospital 12 de Octubre
HC marbella
International Hospital

Under the label of:
9th European Scientific Oncology Conference

Latest Advances on Anticancer Drugs in Clinical Development
WELCOME

We are pleased to welcome you to the 9th European Scientific Oncology Conference (ESOC-9), which will be held in Marbella, on November 3rd - 4th 2016.

Since 2000, we have met every two years in Marbella, in order to analyse and discuss all the new promising anticancer agents in the latest pre-clinical stages or already in Phase I or II clinical studies.

One more year we have invited the most relevant clinical investigators working on the field of new drug development which will actively participate in a comprehensive Scientific Program, with Keynote Lectures from experts and Sessions devoted to the presentation and discussion of individual data from different clinical research groups.

The ESOC Conference is not only an excellent opportunity to learn more about new developments, but it also offers attendees a remarkable forum for discussions, debates and controversies. It will also permit us to meet our colleagues and to enjoy the beautiful city of Marbella.

Thank you for being here with us. We wish you a pleasant and fruitful stay in Marbella!

H. Cortés-Funes
Luis Paz-Ares
J. A. López Martín

Chairmen
Latest Advances on Anticancer Drugs in Clinical Development

CHAIRMEN

Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
José Antonio López Martín, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain

SCIENTIFIC COMMITTEE

Alex A. Adjei, Mayo Clinic, Rochester, USA
Richard Baird, Cambridge Cancer Centre, UK
Hilary Calvert, University of Newcastle, Newcastle, UK
Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Johann de Bono, The Institute of Cancer Research, The Royal Marsden, London, UK
José Antonio López Martín, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Eric Raymond, Swiss Cancer Center-CHUV, Lausanne, Switzerland
Jan Schellens, Netherlands Cancer Institute, Amsterdam, The Netherlands
Jean Charles Soria, Insititut Gustave Roussy, Villejuif, France
Anthony Tolcher, South Texas Accelerated Research Therapeutics, LLC-START, San Antonio, Texas, USA

FACULTY

Alex A. Adjei, Mayo Clinic, Rochester, USA
Richard Baird, Cambridge Cancer Centre, UK
Emiliano Calvo, Centro Integral Oncológico Hospital Clara Campal, Madrid, Spain
Amancio Carnero, Hospital Universitario, Virgen del Rocío, Sevilla, Spain
Manuel Cobo, Hospital Universitario Málaga General, Málaga, Spain
Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Jesús Corral, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Ignacio Durán, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Alejo Efeyan, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain
Sandrine Faivre, Hôpital Beaujon, Clichy, France
Antonio Gualberto, Kura Oncology, Cambridge, Massachusetts, USA
Vicente Guillem, Instituto Valenciano de Oncologia, Valencia, Spain
Payal Kapur, UT Southwestern Medical Center, Dallas, USA
Christophe Le Tourneau, Institut Curie, Paris Saclay University, Paris, France
Spiros Linardopoulos, The Institute of Cancer Research, London, UK
Rafael López, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain
José Antonio López Martín, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Marcos Malumbres, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain
Christophe Massard, Institut Gustave Roussy, Villejuif, France
Ignacio Melero, Clínica Universitaria de Pamplona, Spain
Gabriel Otero, Biotech, London, UK
Luis Paz-Ares, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Héctor Peinado, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain
José Luis Pérez Gracia, Clínica Universitaria de Navarra, Pamplona, Spain
Giuseppe Portella, Università Federico II, Napoli, Italy
Alfonso Quintás-Cardama, Novartis AG, New Jersey, USA
Miguel Ángel Quintela, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid, Spain
Eric Raymond, Saint Joseph Hospital Group, Paris, France
Antonio Rueda, Hospital Costa del Sol, Malaga, Spain
José María Saro, Roche Scientific Innovation Center Zurich, Switzerland
Laureano Simón, Oncomatrix, Bilbao, Spain
Laura Soucek, Hospital Universitario Vall d’Hebron, Barcelona, Spain
José Manuel Trigo, Hospital Universitario Virgen de la Victoria, Málaga
Jon Zugazagoitia, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
Thursday, November 3rd 2016

9:15 am  Welcome and Introduction
Hernán Cortés-Funes (Madrid, Spain)
Luis Paz-Ares (Madrid, Spain)
José Antonio López Martín (Madrid, Spain)

9:30 - 11:15 am  SESSION 1: IMMUNE AGENTS I  Sponsored by
Chairman: José Antonio López Martín (Madrid, Spain)

9:30 am  Anti PD1 Inhibitors: For every patient or only for BMK+ patients?
Luis Paz-Ares (Madrid, Spain)

9:50 am  Biomarkers in Immunotherapy
José Luis Pérez Gracia (Pamplona, Spain)

10:10 am  Oncolytic viruses as immunotherapeutic agents, new opportunities for rare cancer with unmet therapeutic needs?
Guiseppe Portella (Naples, Italy)

10:30 am  Discussion

10:50 am  Coffee break

11:15 - 1:00 pm  SESSION 2: IMMUNE AGENTS II  Sponsored by
Chairmen: Guiseppe Portella (Naples, Italy), Luis Paz-Ares (Madrid, Spain)

11:15 am  IDO Inhibitors
José Antonio López Martín (Madrid, Spain)

11:35 am  Immuno-stimulating agents
Ignacio Melero (Pamplona, Spain)

11:55 am  T Cell Bi-specific Monoclonal Antibodies
José María Saro (Zurich, Switzerland)

12:15 pm  CARTCs in solid tumors
Alfonso Quintás-Cardama (New Jersey, USA)

12:35 pm  Discussion

1:00 pm  Lunch
2:00 - 4:00 pm
SESSION 3: ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND OTHER NOVEL THERAPIES

Chairmen: Rafael López (Santiago de Compostela, Spain), Gabriel Otero (London, UK)

2:00 pm  Rationale and constructions
Gabriel Otero (London, UK)

2:20 pm  Novel HER2-targeting approaches for breast cáncer
Richard Baird (Cambridge, UK)

2:40 pm  ADC antiPTK7
Emiliano Calvo (Madrid, Spain)

3:00 pm  Targeting the tumor microenvironment with ADCs
Laureano Simón (Bilbao, Spain)

3:30 pm  Discussion

3:40 pm  Coffee-break

4:00 - 5:40 pm
SESSION 4: NOVEL TKIS

Chairmen: José Manuel Trigo (Malaga, Spain), Jesús Corral (Sevilla, Spain)

4:00 pm  Third generation EGFR TKIs and resistance
Jesús Corral (Sevilla, Spain)

4:20 pm  Novel Generation ALK Inhibitors
Jon Zugazagoitia (Madrid, Spain)

4:40 pm  ROS/TKR/ RET Inhibitors
Luis Paz-Ares (Madrid, Spain)

5:00 pm  Strategies to enhance CNS penetration of systemic therapies
Richard Baird (Cambridge, UK)

5:20 pm  Discussion

5:40 pm  Adjourn

7:15 pm  Bus departure for Cocktail at HC Marbella

Cocktail

10:00 pm  Return to hotel Andalucía Plaza
Friday, November 4th 2016

9:00 - 10:40 am
SESSION 5: MET INHIBITION
Chairmen: Sandrine Faivre (Clichy, France), Antonio Rueda (Malaga, Spain)

9:00 am MET/HGF relevance for targeted therapy malignancies
Eric Raymond (Paris, France)

9:20 am MET in resistance to TKI
José Manuel Trigo (Málaga, Spain)

9:40 am MET inhibition in hepatobiliary tract tumors
Sandrine Faivre (Clichy, France)

10:00 am MET amplification and MET exon 14 mutations
Emiliano Calvo (Madrid, Spain)

10:20 am Discussion

10:40 am Coffee break

11:00 am Keynote Lecture
Chairman: H, Cortes-Funes (Madrid, Spain)
Drug Development in the era of targeted therapy and immunotherapy
Alex Adjei (Rochester, USA)

11:30 - 1:30 pm
SESSION 6: TARGETING DIFFICULT TARGETS I
Chairmen: José Luis Pérez Gracia (Pamplona, Spain), Spiros Linardopoulos (London, UK)

11:30 am Targeting the RAS-ERK pathway
Antonio Gualberto (Cambridge, USA)

11:50 am Ras Family
Alex Adjei (Rochester USA)

12:10 pm Targeting MYC by a new generation of cell penetrating peptides
Laura Soucek (Barcelona, Spain)
12:30 pm  CDK inhibitors  
Marcos Malumbres (Madrid, Spain)

12:50 pm  Discussion

1:10 pm  Lunch

2:10 - 3.30 pm
 SESSION 7: TARGETING DIFFICULT TARGETS II
Chairmen: Manuel Cobo (Málaga, Spain), Marcos Malumbres (Madrid, Spain)

2:10 pm  Targeting tumor suppressor genes  
Amancio Carnero (Sevilla, Spain)

2:30 pm  MPS1/TTK inhibition: A Novel Approach in Breast Cancer Treatment  
Spiros Linardopoulos (London, UK)

2:50 pm  BET inhibitors  
Eric Raymond (Paris, France)

3:10 pm  Discussion

3:30 - 5:10 pm
 SESSION 8: PRECISION ONC/OLOGY MEDICINE
Chairmen: Vicente Guillem (Valencia, Spain), Luis Paz-Ares (Madrid, Spain)

3:30 pm  How to choose a platform and the best gene panel?  
Christophe Le Tourneau (Paris, France)

3:50 pm  Circulating exosomes, towards the future of liquid biopsy  
Héctor Peinado (Madrid, Spain)

4:10 pm  Do we need a molecular tumor board?  
Christophe Massard (Villejuif, France)

4:30 pm  Round table discussion:
Hernán Cortés-Funes (Madrid, Spain)  
Christophe Le Tourneau (Paris, France)  
Héctor Peinado (Madrid, Spain)  
Christophe Massard (Villejuif, France)

4:50 pm  Coffee break
SESSION 9: HYPOXIA AND METABOLISM

5:10 pm **Beyond Rapamycin-Nutrient signalling in cancer**
Alejo Efeyan (Madrid, Spain)

5:30 pm **Novel HIF2 inhibitors**
Payal Kapur (Dallas, Texas)

5:50 pm **Hypoxia in Cancer Therapy**
Amancio Carnero (Sevilla, Spain)

6:10 pm **Discussion**

6:30 pm **CLOSING REMARKS**
Hernán Cortés-Funes (Madrid, Spain)
Comprometidos en acelerar la transición desde la investigación a la práctica clínica.

—David Kaufman, MD, PhD
Director, MSD Oncology Clinical Research
GENERAL INFORMATION

VENUE

Hotel Andalucía Plaza ****
Urb. Nueva Andalucía s/n
E-29660 Puerto Banús, Marbella, Spain
Web: www.hotelh10andaluciaplaza.com

CONFERENCE SECRETARIAT

BN&Co. Congress and Event Management
Paseo de la Castellana 179 - Entreplanta
28046 MADRID - Spain
Phone : +34 91 571 93 90 | +34 91 571 92 10
Fax : +34 91 571 92 06
E-mail: c.lazaro@bnyco.com
Web: www.bnyco.com

ACCREDITATION

The Conference has applied for the Accreditation on Continuing Education Activities of Health Professions.
Once the accreditation is approved, a certificate will be delivered to all the participants. The attendance to all sessions is mandatory in order to receive the corresponding certificate.

REGISTRATION

Onsite Registration fee is 450€ (taxes included)
Onsite Registration for Physicians in Training is 200€ (taxes included)
LANGUAGE
The official language of the Symposium is English. There will be no simultaneous interpretation.

INSURANCE
The organisers will not be responsible for individual, medical, travel or personal insurance. Participants are advised to take out their own personal insurance policies.

NO SMOKING
Smoking will be forbidden in all Conference areas.

MOBILE PHONES
Mobile phones must be disconnected during all the sessions.
9th European Scientific Oncology Conference

Latest Advances on Anticancer Drugs in Clinical Development

Marbella, Spain, November 3rd-4th, 2016

www.esocmarbella.com

Conference Secretariat:

BN&Co. Congress and Event Management
Paseo de la Castellana 179 - entreplanta, 28046 Madrid
Tel. +34 91 571 93 90 • E-mail: c.lazaro@bnyco.com